**Supplementary tables**

**Supplementary Table 1 Six-month and 1-, 2-, and 3- year survival (with 95% confidence intervals) by variable.**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Predictive factor |  | 0.5-Year  (95% CI) | 1-Year  (95% CI) | 2-Year  (95% CI) | 3-Year  (95% CI) | pa |
| Hemoglobin (**g/dl**) | ≥ 12 | 71.15% (67.92, 74.53) | 48.15% (44.64, 51.95) | 23.07% (20.18, 26.38) | 15.69% (13.21, 18.64) | 0.008 |
|  | <12 | 65.68% (59.56, 72.43) | 35.96% (30.00, 43.09) | 18.10% (13.55, 24.18) | 10.51% (7.03, 15.72) |  |
| PLR | <210 | 76.09% (72.70, 79.64) | 50.91% (46.99, 55.16) | 26.21% (22.85, 30.07) | 17.20% (14.34, 20.63) | <.0001 |
|  | ≥ 210 | 59.77% (54.87, 65.11) | 36.26% (31.58, 41.64) | 14.93% (11.63, 19.16) | 10.09% (7.36, 13.85) |  |
| RDW | <15 | 72.56% (69.48, 75.76) | 49.05% (45.64, 52.70) | 23.55% (20.73, 26.76) | 15.61% (13.22, 18.44) | <.0001 |
|  | ≥ 15 | 57.03% (49.81, 65.30) | 27.56% (21.38, 35.52) | 14.10% (9.57, 20.76) | 9.09% (5.45, 15.15) |  |
| NLR | <5 | 78.92% (75.75, 82.21) | 53.88% (50.06, 57.99) | 27.32% (23.99, 31.12) | 17.61% (14.79, 20.97) | <.0001 |
|  | ≥ 5 | 52.83% (47.64, 58.57) | 29.21% (24.64, 34.62) | 11.73% (8.68, 15.84) | 8.69% (6.07, 12.46) |  |

Abbreviations: NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; RDW, red cell distribution width. aP-value calculated using log rank test .

**Supplementary Table 2** Univariate Cox Regression Model for Overall Survival in extensive stage SCLC.

|  |  |  |  |
| --- | --- | --- | --- |
| **Variable** | **HR** | **95% CI** | **P-value** |
| **Significant factors** |  |  |  |
| Loge (NLR) | 1.62 | 1.44 to 1.82 | <0.0001 |
| Loge (RDW) | 3.65 | 1.83 to 7.26 | 0.0002 |
| PLR (***v*** <210) |  |  |  |
| ≥ 210 | 1.198 | 1.008 to 1.423 | 0.04 |
| Age at diagnosis | 1.022 | 1.012 to 1.031 | <0.0001 |
| Gender (***v*** female) |  |  |  |
| Male | 1.22 | 1.03 to 1.45 | 0.0207 |
| ECOG performance status (***v*** <2) |  |  |  |
| ≥ 2 | 3.54 | 2.91 to 4.31 | <0.0001 |
| Chest radiation (***v*** no) |  |  |  |
| Yes | 0.62 | 0.52 to 0.75 | <0.0001 |
| Chemotherapy (***v*** no) |  |  |  |
| Yes | 0.15 | 0.12 to 0.19 | <0.0001 |
| Liver metastases (***v*** no) |  |  |  |
| Yes | 1.32 | 1.11 to 1.57 | 0.0017 |
| **Numbers of m**etastatic sites (***v*** <2) |  |  |  |
| ≥ 2 | 1.27 | 1.06 to 1.52 | 0.0094 |
| **Nonsignificant factors** |  |  |  |
| Smoking status (***v*** former) |  |  |  |
| Current | 1.02 | 0.86 to 1.22 | 0.7985 |
| Pack-years smoked (***v*** 0-20) |  |  | 0.0809 |
| 20-40 | 0.68 | 0.49 to 0.95 |  |
| 40-60 | 0.83 | 0.59 to 1.15 |  |
| >60 | 0.715 | 0.518 to 0.987 |  |
| Smoking cessation (***v*** quit) |  |  |  |
| never quit | 1.13 | 0.94 to 1.35 | 0.1998 |
| BMI (***v*** <25) |  |  | 0.6826 |
| 25 to 30 | 1.09 | 0.90 to 1.33 |  |
| >30 | 1.05 | 0.83 to 1.32 |  |
| Hemoglobin(g/dl)  (***v*** ≥ 12) |  |  |  |
| <12 | 1.148 | 0.939 to 1.404 | 0.1793 |
| CNS metastases (***v*** no) |  |  |  |
| Yes | 1.00 | 0.80 to 1.24 | 0.9774 |
| Lung metastases (***v*** no) |  |  |  |
| Yes | 0.94 | 0.71 to 1.25 | 0.6852 |
| Pleural metastases (***v*** no) |  |  |  |
| Yes | 1.06 | 0.77 to 1.45 | 0.7235 |
| Adrenal metastases (***v*** no) |  |  |  |
| Yes | 1.21 | 0.94 to 1.55 | 0.1387 |
| Any other cancer (***v*** no) |  |  |  |
| Yes | 0.96 | 0.77 to 1.21 | 0.7435 |
| COPD (***v*** no) |  |  |  |
| Yes | 0.94 | 0.77 to 1.14 | 0.5021 |
| Diabetes (***v*** no) |  |  |  |
| Yes | 0.81 | 0.62 to 1.05 | 0.1172 |
| Cardiovascular disease (***v*** no) |  |  |  |
| Yes | 1.07 | 0.89 to 1.30 | 0.4716 |
| SCS (***v*** <9) |  |  |  |
| ≥ 9 | 0.80 | 0.62 to 1.02 | 0.0661 |

Abbreviations: NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; RDW, red cell distribution width; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; BMI, body mass index; CNS, central nervous system; COPD, chronic obstructive pulmonary disease; SCS, simplified comorbidity score.

.

**Supplementary Table 3** Univariate Cox Regression Model for Overall Survival in limited stage SCLC.

|  |  |  |  |
| --- | --- | --- | --- |
| **Variable** | **HR** | **95% CI** | **P-value** |
| **Significant factors** |  |  |  |
| PLR (***v*** <210) |  |  |  |
| ≥ 210 | 1.55 | 1.23 to 1.97 | 0.0002 |
| Loge (NLR) | 1.2 | 1.012 to 1.423 | 0.0358 |
| Loge (RDW) | 3.524 | 1.212 to10.249 | 0.0208 |
| Hemoglobin(g/dl) (***v*** ≥ 12) |  |  |  |
| <12 | 1.35 | 1.03 to 1.76 | 0.0268 |
| Age at diagnosis | 1.04 | 1.03 to 1.05 | <0.0001 |
| ECOG performance status (***v*** <2) |  |  |  |
| ≥ 2 | 1.97 | 1.45 to 2.66 | <0.0001 |
| Smoking cessation (***v*** quit) |  |  |  |
| Never quit | 1.53 | 1.20 to 1.94 | 0.0005 |
| Chest radiation (***v*** no) |  |  |  |
| Yes | 0.52 | 0.41 to 0.65 | <0.0001 |
| Chemotherapy (***v*** no) |  |  |  |
| Yes | 0.17 | 0.12 to 0.24 | <0.0001 |
| Surgery (***v*** no) |  |  |  |
| Yes | 0.67 | 0.48 to 0.95 | 0.0228 |
| Prophylactic cranial irradiation (***v*** no) |  |  |  |
| Yes | 0.46 | 0.35 to 0.61 | <0.0001 |
| **Nonsignificant factors** |  |  |  |
| Gender (***v*** female) |  |  |  |
| Male | 1.02 | 0.82 to 1.28 | 0.8326 |
| Smoking status (***v*** former) |  |  |  |
| Current | 1.06 | 0.84 to 1.33 | 0.6292 |
| Pack-years smoked (***v*** 0-20) |  |  | 0.1187 |
| 20-40 | 0.50 | 0.28 to 0.88 |  |
| 40-60 | 0.586 | 0.341 to 1.009 |  |
| >60 | 0.57 | 0.33 to 0.98 |  |
| BMI (***v*** <25) |  |  | 0.9521 |
| 25 to 30 | 0.99 | 0.77 to 1.28 |  |
| >30 | 0.96 | 0.71 to 1.28 |  |
| Any other cancer (***v*** no) |  |  |  |
| Yes | 0.84 | 0.64 to 1.12 | 0.2338 |
| COPD (***v*** no) |  |  |  |
| Yes | 1.11 | 0.88 to 1.39 | 0.3788 |
| Diabetes (***v*** no) |  |  |  |
| Yes | 0.89 | 0.64 to 1.23 | 0.4870 |
| Cardiovascular disease (***v*** no) |  |  |  |
| Yes | 1.02 | 0.81 to 1.29 | 0.8480 |
| SCS (***v*** <9) |  |  |  |
| ≥ 9 | 0.84 | 0.64 to 1.10 | 0.1995 |

Abbreviations: NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; RDW, red cell distribution width; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; BMI, body mass index; COPD, chronic obstructive pulmonary disease; SCS, simplified comorbidity score.